Beigene, Ltd. (NASDAQ:ONC – Get Free Report) COO Xiaobin Wu sold 30,654 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $240.74, for a total value of $7,379,643.96. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Xiaobin Wu also recently made the following trade(s):
- On Thursday, February 20th, Xiaobin Wu sold 21,267 shares of Beigene stock. The stock was sold at an average price of $240.07, for a total transaction of $5,105,568.69.
Beigene Stock Performance
NASDAQ:ONC opened at $255.37 on Friday. Beigene, Ltd. has a fifty-two week low of $126.97 and a fifty-two week high of $260.98. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. The firm has a market cap of $24.99 billion, a price-to-earnings ratio of -30.99, a P/E/G ratio of 9.44 and a beta of 0.63.
Beigene Company Profile
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Recommended Stories
- Five stocks we like better than Beigene
- Want to Profit on the Downtrend? Downtrends, Explained.
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- How to Use the MarketBeat Excel Dividend Calculator
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- Buy P&G Now, Before It Sets A New All-Time High
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.
